2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 944

Long-Term Survival and Follow-up of Anti-Th/to Antibody Positive Systemic Sclerosis Patients
Abstract Number: 2736

Long-Term Survival in Systemic Necrotizing Vasculitides
Abstract Number: 371

Longer Term Outcomes of Chronic Relapsing Multifocal Osteomyelitis in a UK Tertiary Adolescent and Young Adult Rheumatology Centre
Abstract Number: 1500

Longitudinal Analysis of Different Therapeutic Strategies in Patients with Primary Sjögren’s Syndrome
Abstract Number: 785

Longitudinal Angiographic Findings in Patients with Takayasu’s Arteritis
Abstract Number: 2808

Longitudinal Assessment of Cognitive Function in SLE: Identification of Trajectories
Abstract Number: 933

Longitudinal Association between Sleep Quality and Knee Pain in the Multicenter Osteoarthritis Study
Abstract Number: 32

Longitudinal Associations between Rheumatoid Factor and Ex Vivo Cytokine Production Reveal Novel Mechanistic Insights into Rheumatoid Arthritis
Abstract Number: 1495

Longitudinal Changes in EULAR Sjögren’s Syndrome Patient Reported Index in Routine Clinical Practice
Abstract Number: 2432

Longitudinal Changes in Gene Expression Associated with Disease Activity during Pregnancy and Post-Partum Among Women with Rheumatoid Arthritis
Abstract Number: 1864

Longitudinal Changes in Serum Uric Acid Levels and Associated Risk of Cardiometabolic Events and Renal Insufficiency in Gout Patients
Abstract Number: 2131

Longitudinal Cohort Study of Anti-PM/Scl Myositis Patients: Mild Muscle and Lung Involvement with Prominent Perivascular Inflammation
Abstract Number: 1639

Longitudinal Evolution in a Nationwide Cohort Originally Classified As Mixed Connective Tissue Disease
Abstract Number: 1277

Longitudinal Predictors of Physical Function in Juvenile Myositis
Abstract Number: 1891

Low Alkaline Phosphatase Levels: Could It be Hypophosphatasia?

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].